Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice.
As a part of the ILSI-HESI Alternative to Carcinogenicity Testing (ACT) program, we performed a 26-week carcinogenetic study of nonmutagenic drug, ampicillin (ABPC) in Tg-rasH2 mice. ABPC was given to Tg-rasH2 mice (0, 350, 1000, 3000 mg/kg, p.o.) and Non-Tg mice (0, 3000 mg/kg, p.o.) daily for 26 weeks. As a positive control, a single dose of MNU was administered once to Tg-rasH2 mice (75 mg/kg, i.p.). In this study, Tg-rasH2 mice did not demonstrate any increases in tumor development in response to ABPC. Thus, ABPC had no carcinogenicity in the 26-week carcinogenesis study in Tg-rasH2 mice or in a 2-year carcinogenesis study in B6C3F1 mice.
Adachi
Tamiko
T
Safety Research Laboratory, Tanabe Seiyaku Co., Ltd., 3-16-89 Kashima, Yodogawa-ku, Osaka 532-8505, Japan.
Kuwamura
Yuki
Y
Fujiwara
Toshihisa
T
Tanimoto
Noriaki
N
Nishimura
Tomonari
T
Koguchi
Atsushi
A
Kobayashi
Kinji
K
Sasaki
Yoshifumi
Y
Yamaguchi
Chisato
C
Honda
Tatsuya
T
Kawashima
Kazutaka
K
Yuasa
Hirofumi
H
Yamamura
Takaaki
T
Inui
Toshihide
T
D000284:Administration, Oral; D000667:Ampicillin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D011905:Genes, ras; D008136:Longevity / Q000187:drug effects; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D009374:Neoplasms, Experimental / Q000139:chemically induced* / Q000473:pathology; D010406:Penicillins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*
D002273:Carcinogens; D010406:Penicillins; D000667:Ampicillin